patients. Thus far, transvalvular gradients and aortic valve areas seem to be not unfavourable for performing TAVI. Accordingly, data collection in GARY in 2018 and 2019 has focused on a patient subcohort from 70 to 79 years of age, encompassing long-term durability of SAVR and TAVI prostheses and in particular, have been recruited to also undergo standardized follow-up echocardiography for at least 10 years.
The ethics of waiting lists for TAVR procedures
During the last decade, transcatheter aortic valve replacement (TAVR), as a treatment option for symptomatic severe aortic valve stenosis, has created a paradigm shift in treatment.
Introduced initially as 'rescue' treatment for inoperable patients, TAVR is currently a viable option for high-, intermediate-, and (soon) low-surgical risk patients. As with other newly developed innovative biomedical technologies, the absolute cost of TAVR is high. 1 Thus, reimbursement and affordability issues have resulted in restricted (or in places, centrally controlled) capacity for TAVR. Consequently, a demand-capacity imbalance leads to long waiting times. Waiting lists have been identified as the second most important ethical challenge facing patients and their families in healthcare, according to a survey conducted by a panel of 12 clinical bioethicists in Toronto, Canada. 2 However, very limited evidence exists on waiting times for TAVR and most importantly on its consequences. 3 As far as the waiting time for TAVR is concerned, a study of 378 patients from three hospitals reported a median waiting time of 71 days, 4 whereas in another study of 4461 patients referred for TAVR in Canada, the median waiting time was 80 days. 5 Currently, there are no guidelines for an 'acceptable' TAVR waiting time. According to the Canadian Wait-Time Alliance, the suggested maximum waiting time for surgical aortic valve replacement (SAVR) is 42 days which is shorter than the reported TAVR waiting times. 3 Although data from Europe will undeniably be variable, waiting times may be even longer, particularly in countries with tighter financial policies. In a small study from Spain, TAVR was performed more than 6 months (180 days) after initial indication in almost 60% of patients. 6 The critical question is whether any longer waiting time for TAVR compared to SAVR is clinically meaningful and ethically justifiable, especially for inoperable and/or patients with high surgical risk. A potential answer could be given by understanding the magnitude of adverse consequences that occur during the waiting period before TAVR and if there is an association with patient outcomes and prognosis 7 or even cost-effectiveness. 6 The theoretical impact of a longer waiting time on the effectiveness of TAVR was recently explored in silico, 8 by a mathematical simulation model using data from published randomized clinical trials. It was found that TAVR waiting times beyond 60 days would negate any potential benefit of TAVR over traditional SAVR. 8 This study concluded that modest increases in TAVR wait times would have a substantial effect on TAVR effectiveness in inoperable patients and high-risk surgical candidates. 8 Prolonged waiting time for needed medical care may compromise the health status and prognosis of patients, impede their ability to return to normal function at work and at home and may also contribute to psychological distress 2 (see Figure) .
Taking into consideration (i) the recent approval by the Food and Drug Administration of TAVR for low-risk patients, (ii) the expected expansion of recommendations from European and American guidelines, and (iii) the fact that low-risk patient subset constitutes the 80% of patients with aortic stenosis currently treated surgically, 9 a basis for a forthcoming 'epidemy' is delineated. This, of note, will refer to younger patient populations than those currently offered TAVR. One must also bear in mind that the need for an alternative treatment was founded on the observation that more than 30% of octogenarians with severe symptomatic aortic stenosis were not offered any treatment at all, 10 based on their prohibitive surgical risk and/or, in the complex physician-driven decision making. Hence, under current socio-economic conditions, waiting times for TAVR are expected to increase further. If not addressed timely, the community will soon face an awkward decision: who will be treated first? The younger or the older and/or the frailer? For the record, the latter patient subset, once deprived from surgery, is the one which introduced and established TAVR to the community.
Optimal management of patients on waiting lists for TAVR may be difficult considering the fulfilment of the five main principles in medical ethics:
(i) 'Respect for autonomy' where patients have the right to refuse or choose their treatment, but prolonged waiting lists could counteract their autonomy. (ii) 'Beneficence' where the physician should act in the best interest of the patient, but the prolongation of waiting time for TAVR might be harmful for patients' condition or prognosis. (iii) 'Non-maleficence' meaning not be the cause of harm should be considered in cases were a long waiting time for some patients might provoke health deterioration, (iv) 'Utility' meaning to promote more good than harm cannot be secured for every patient on a waiting list for TAVR if there is no prioritization protocol according to patient risk, and (v) 'Justice' which concerns the distribution of scarce health resources and the decision of who gets what treatment which does not apply equally for every hospital and healthcare system.
In summary, waiting lists and their management is a multifactorial clinical and ethical problem facing physicians, patients, healthcare systems, and governments. Under the light of recent clinical trials 11,12 and FDA approval of TAVR for low-risk patients, the establishment of standardized procedures and guidelines about the criteria for being placed on a waiting list for TAVR and how to prioritize patients once they join a list is now more needed and might eliminate in some degree the ethical dilemmas emerging from the problem of scarce resources. Therefore, in health systems in which diagnosis-treatment delays exist, for patients eligible for TAVR but with an option for SAVR the physician-patient shared decision process should also take into account waiting times, while proper prioritization should be sought for the truly inoperable patients.
